Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment

Publication

Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment

Journal Paper/Review - Aug 7, 2015

Hitz Felicitas, Villa D, Shenkier T, Sehn L H, Savage K J, Moccia A, Hoskins P, Gascoyne R D, Connors J M, Klasa R

Citation

Hitz F, Villa D, Shenkier T, Sehn L, Savage K, Moccia A, Hoskins P, Gascoyne R, Connors J, Klasa R. Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment. Ann Hematol 2015; 94:1839-43.

Type

Journal Paper/Review (English)

Journal

Ann Hematol 2015; 94

Publication Date

Aug 7, 2015

Issn Electronic

1432-0584

Pages

1839-43

Brief description/objective

Primary refractory diffuse large B cell lymphoma (DLBCL) following R-CHOP chemotherapy is a major concern. We identified 1126 patients with DLBCL treated with R-CHOP from 2000 to 2009, of whom 166 (15 %) had primary refractory disease. Of the 75/166 (45 %) who were age <70 years and had been planned for stage-directed curative therapy, 43 (57 %) were primary nonresponders and 32 (43 %) relapsed within 3 months of completing R-CHOP. Thirty of 75 (40 %) patients had serious comorbidity and organ dysfunction precluding intensive treatment and had palliative treatment only. Twelve of 45 (27 %) patients responded to second-line treatment and underwent ASCT. The median overall survival for the 75 patients was 10 months with only seven patients alive without evidence of disease at follow-up ranging from 14 to 106 months. Primary refractory DLBCL after R-CHOP has a very poor outcome with only anecdotal survivors independent of the intended treatment approach.